

## **ANAC, Anacor Pharmaceuticals, announce positive results, 03/22/2013**

### **Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis**

**PALO ALTO, Calif.--(BUSINESS WIRE)--**

**Anacor Pharmaceuticals ( [ANAC](#) ) today announced positive results from a Phase 2 dose-ranging trial ( AN2728-AD-204**

**) of its topical boron-based phosphodiesterase-4**

**( PDE-4 ) inhibitor, AN2728**

**. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate**

**atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728**

**ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their**

**Atopic**

**Dermatitis Severity Index (**

**ADSI**

**) score, with 66% of lesions in this treatment group achieving total or partial clearance.**

**AN2728**

**was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.**

**“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of**

**Anacor**

**Pharmaceuticals. “In all arms of the study, lesions treated with AN2728**

**ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians.**

**AN2728**

**also continues to demonstrate an excellent safety profile - a key factor in treating this disease that primarily affects children.”**

**“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfi**  
**eld,**

**M.D., Chief of Pediatric and Adolescent Dermatology and  
Professor of Pediatrics and Medicine (Dermatology) at  
Rady**

**Children's Hospital, University of California, San Diego.**

**“AN2728**

**has the potential to be an outstanding addition to the treatment  
armamentarium for physicians and a great benefit to children with  
atopic  
dermatitis.”**

Sources: Anacor Pharma, [OxBridge Research](#), [Daily Stock Deals](#)

**Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!**  
®

**Get the Fresh, Nutrient Rich, Piping Hot Picks  
Everyday! Sign-up, its FREE!**